Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
A preview of the April 1 FDA advisory panel convened to review MannKind's inhaled insulin device.
Synta isn't saying why Safi Bahcall resigned as CEO but the stock has severely underperformed the market for the past year.
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
An epic month of biotech stock performance ends with a significant sell off.
If history repeats, investor optimism for NewLink's phase III study is misplaced.
InterMune's Esbriet improved lung function and delayed disease progression in pivotal phase III study.
An investor short Endocyte explains his negative view on the upcoming European approval decision in ovarian cancer and why the lung cancer study is likely to fail.
The No. 1 stock on this list has more than half its float short.